Last reviewed · How we verify
TNF-alpha antagonists
At a glance
| Generic name | TNF-alpha antagonists |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis (PHASE2)
- Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis (PHASE3)
- Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not? (NA)
- Therapeutic Response to Tumor Necrosis Factor-alpha (TNF-alpha) Antagonists in Rheumatoid Arthritis.
- Predicting Response to Standardized Pediatric Colitis Therapy (PHASE4)
- Treatment Outcome of Uveitis in Autoimmune Diseases
- TNF-alpha Antagonists for AECOPD: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial (PHASE2, PHASE3)
- Mother-caregivers of Children With Duchenne Muscular Dystrophy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |